One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

B. Glintborg; I.J. Sørensen; E. Omerovic; F. Mehnert; N. Manilo; K. Danebod; D.V. Jensen; H. Nordin; A.G. Loft; O. Hendricks; S. Chrysidis; B.L. Andersen; J.L. Raun; H. Lindegaard; J. Espesen; S.H. Jakobsen; I.M.J. Hansen; E.B. Dalsgaard; D.D. Pedersen; S. Kristensen; A. Linauskas; L.S. Andersen; J. Grydehøj; N. Krogh; M.L. Hetland

doi:10.1136/annrheumdis-2018-eular.2113

One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

B. Glintborg, I.J. Sørensen, E. Omerovic, F. Mehnert, N. Manilo, K. Danebod, D.V. Jensen, H. Nordin, A.G. Loft, O. Hendricks, S. Chrysidis, B.L. Andersen, J.L. Raun, H. Lindegaard, J. Espesen, S.H. Jakobsen, I.M.J. Hansen, E.B. Dalsgaard, D.D. Pedersen, S. KristensenA. Linauskas, L.S. Andersen, J. Grydehøj, N. Krogh, M.L. Hetland

Department of Clinical Medicine

4 Citations (Scopus)

Original language	English
Article number	THU0189
Journal	Annals of the Rheumatic Diseases
Volume	77
Issue number	Suppl 2
Pages (from-to)	313-314
ISSN	0003-4967
DOIs	https://doi.org/10.1136/annrheumdis-2018-eular.2113
Publication status	Published - 2018

Access to Document

10.1136/annrheumdis-2018-eular.2113

313.full.pdfFinal published version, 683 KB

http://ard.bmj.com/lookup/doi/10.1136/annrheumdis-2018-eular.2113

Cite this

Glintborg, B., Sørensen, I. J., Omerovic, E., Mehnert, F., Manilo, N., Danebod, K., Jensen, D. V., Nordin, H., Loft, A. G., Hendricks, O., Chrysidis, S., Andersen, B. L., Raun, J. L., Lindegaard, H., Espesen, J., Jakobsen, S. H., Hansen, I. M. J., Dalsgaard, E. B., Pedersen, D. D., ... Hetland, M. L. (2018). One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. Annals of the Rheumatic Diseases, 77(Suppl 2), 313-314. Article THU0189. https://doi.org/10.1136/annrheumdis-2018-eular.2113

One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. / Glintborg, B.; Sørensen, I.J.; Omerovic, E. et al.
In: Annals of the Rheumatic Diseases, Vol. 77, No. Suppl 2, THU0189, 2018, p. 313-314.

Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

Glintborg, B, Sørensen, IJ, Omerovic, E, Mehnert, F, Manilo, N, Danebod, K, Jensen, DV, Nordin, H, Loft, AG, Hendricks, O, Chrysidis, S, Andersen, BL, Raun, JL, Lindegaard, H, Espesen, J, Jakobsen, SH, Hansen, IMJ, Dalsgaard, EB, Pedersen, DD, Kristensen, S, Linauskas, A, Andersen, LS, Grydehøj, J, Krogh, N & Hetland, ML 2018, 'One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry', Annals of the Rheumatic Diseases, vol. 77, no. Suppl 2, THU0189, pp. 313-314. https://doi.org/10.1136/annrheumdis-2018-eular.2113

Glintborg B, Sørensen IJ, Omerovic E, Mehnert F, Manilo N, Danebod K et al. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry. Annals of the Rheumatic Diseases. 2018;77(Suppl 2):313-314. THU0189. doi: 10.1136/annrheumdis-2018-eular.2113

@article{bd9deee7a6544956a8716755377a2d37,

title = "One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry",

author = "B. Glintborg and I.J. S{\o}rensen and E. Omerovic and F. Mehnert and N. Manilo and K. Danebod and D.V. Jensen and H. Nordin and A.G. Loft and O. Hendricks and S. Chrysidis and B.L. Andersen and J.L. Raun and H. Lindegaard and J. Espesen and S.H. Jakobsen and I.M.J. Hansen and E.B. Dalsgaard and D.D. Pedersen and S. Kristensen and A. Linauskas and L.S. Andersen and J. Grydeh{\o}j and N. Krogh and M.L. Hetland",

year = "2018",

doi = "10.1136/annrheumdis-2018-eular.2113",

language = "English",

volume = "77",

pages = "313--314",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "Suppl 2",

}

TY - ABST

T1 - One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the danbio registry

AU - Glintborg, B.

AU - Sørensen, I.J.

AU - Omerovic, E.

AU - Mehnert, F.

AU - Manilo, N.

AU - Danebod, K.

AU - Jensen, D.V.

AU - Nordin, H.

AU - Loft, A.G.

AU - Hendricks, O.

AU - Chrysidis, S.

AU - Andersen, B.L.

AU - Raun, J.L.

AU - Lindegaard, H.

AU - Espesen, J.

AU - Jakobsen, S.H.

AU - Hansen, I.M.J.

AU - Dalsgaard, E.B.

AU - Pedersen, D.D.

AU - Kristensen, S.

AU - Linauskas, A.

AU - Andersen, L.S.

AU - Grydehøj, J.

AU - Krogh, N.

AU - Hetland, M.L.

PY - 2018

Y1 - 2018

U2 - 10.1136/annrheumdis-2018-eular.2113

DO - 10.1136/annrheumdis-2018-eular.2113

M3 - Conference abstract in journal

SN - 0003-4967

VL - 77

SP - 313

EP - 314

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - Suppl 2

M1 - THU0189

ER -